Vera治疗技术公司为推进自发免疫性疾病治疗而筹集了261M元的库存。 Vera Therapeutics raises $261M in stock offering to advance autoimmune disease treatments.

Vera治疗公司以610万股的价格公开出价,每股42.50美元,在开销前筹集了约2.61亿美元,承保人可以选择购买更多的股票。 Vera Therapeutics priced a public offering of 6.1 million shares at $42.50 each, raising about $261 million before expenses, with an option for underwriters to buy more shares. 这项提议定于2025年12月11日结束,由主要投资银行管理,并使用2024年10月提交的交存登记。 The offering, set to close December 11, 2025, is managed by major investment banks and uses a shelf registration filed in October 2024. 该公司正在推进自身免疫性疾病的治疗方法,包括Igan和狼性炎的阿塔西塞普,以及其他两种候选药物正在开发中. The company is advancing treatments for autoimmune diseases, including atacicept for IgAN and lupus nephritis, and two other candidates in development.